Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors

Digestive System Tumors Clinical Trial

Official title: A Phase I/II Phase Evaluating the Effectiveness and Safety of CDK4/6 Inhibitor (TQB3616) Combined With PD-L1 Monoclonal Antibody (TQB2450) in the Treatment of PD-1/PD-L1 Monoclonal Antibody Resistance and Abnormal Cell Cycle Digestive System Tumors.

Status Not yet recruiting

Clinical Trial Summary

This study intends to explore the effectiveness and safety of CDK4/6 inhibitor (TQB3616) combined with PD-L1 monoclonal antibody (TQB2450) in the treatment of PD-1/PD-L1 monoclonal antibody resistance and abnormal cell cycle digestive system tumors, through prospective Explore to provide more evidence-based medical evidence for precision immunotherapy for patients with digestive system tumors.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Digestive System Neoplasms
• Digestive System Tumors
• Gastrointestinal Neoplasms

• NCT number: NCT05139082
• Study type: Interventional
• Source: Peking University
• Contact: Lin Shen, master
• Phone: 13911219511
• Email: doctorshenlin@sina.cn
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: November 24, 2021
• Completion date: October 1, 2023